A Phase 3 interventional study of 5 mL of 0.5% preservative-free bupivacaine in PTSD, sponsored by The Royal's Institute of Mental Health Research. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-07-25.
Sponsored by The Royal's Institute of Mental Health Research · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada — 34 open to participants now, 42 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 56th largest by planned enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2024, is one of 3 in phase 3, reaches primary completion later than 11 of the 41 other live ones, and was the 85th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →34 of the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–65
COMPASS Pathways · Sites in Canada, United States
Ages 18+
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Women only
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 22 · Phase 3 8 · Phase 4 2
First in 2007; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 54 across the 113 interventional studies, 303 across the 14 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 127 have an industry lead sponsor. The 10 most frequent:
The Royal's Institute of Mental Health Research is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
The Royal's Institute of Mental Health Research has 2 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Stress Disorders, Post-Traumatic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT07309302Université du Québec a MontréalPsychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT06044675RemedyMDMA-Assisted CBCT for PTSD vs CBCT RCT | 2027-03-31 |
| NCT06335043London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPersonalized Pharmacotherapy Using Pharmacogenetics in Veterans | 2027-04-25 |
Add all 7 to your calendar (.ics) → With an account.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The most common treatment for Posttraumatic Stress Disorder (PTSD) is trauma-focused therapy and/or prescription of medication(s). However, these treatments may not directly reduce symptoms associated with PTSD, making it difficult for patients to be treated for this condition and recover. Stellate ganglion block (SGB) is a medical procedure that involves injection of a local anesthetic (a medication that causes reduced sensation/feeling in a given area) around the stellate ganglion, which is a collection of nerves near the base of the neck. This procedure causes a short-lived, temporary shutdown of nerve signals (up to 5-7 hours) and is commonly performed in Canada for certain pain and medical conditions. In the last decade, several studies, including those involving members of military groups, have shown that SGB can result in a rapid and sustained drop in symptoms related to PTSD such as overwhelming anxiety, increased irritability, heightened alertness, and exaggerated startle. Considering these results and the known safety of this procedure (as demonstrated by previous research and use in other illnesses), SGB has been increasingly used to treat PTSD among veterans in the United States but has not yet been evaluated in Canada. More research is thereby needed to use SBG as a method of PTSD treatment in Canada, and to better understand how it works to reduce symptoms associated with this condition. Health Canada, the organization which oversees clinical trials such as this one, has not approved the use of the SGB procedure for PTSD in the general population, however Health Canada has allowed the use of SGB in this study to better understand how it works and how it may be used in the future to treat PTSD-related symptoms in those who feel that common treatments are not effective.
Posttraumatic Stress Disorder (PTSD) is a trauma- and stress-related disorder arising from an experienced or witnessed traumatic event, most commonly actual or threatened death, serious injury, or sexual violence. There is a distinct pattern of intrusion and avoidance, as well as negative alterations in cognitions, mood, arousal, and reactivity, leading to serious impairments in personal, social and occupational functioning. The risk of PTSD is elevated in military and public safety personnel, and first responders. Despite advances in evidence-based treatments for PTSD, optimal outcomes are often not achieved, particularly in military veterans. One of the treatment-interfering factors is persistent hyperarousal (abnormally heightened state of anxiety and alertness), which prevents engagement in trauma processing and contributes to medication intolerance and substance misuse. The search for novel methods to target hyperarousal and underlying responses of the sympathetic nervous system have provided some promising pharmacologic approaches, such as the use of the adrenergic (adrenaline-related) blockers propranolol and prazosin. There is a need for novel and complementary approaches to normalize sympathetic (fight-or-flight) regulation in PTSD to provide symptom relief and facilitate its treatment and recovery.
Stellate ganglion block (SGB) is a medical procedure that involves injection of local anesthetic around the stellate ganglion, which is a collection of sympathetic (fight-or-flight) nerves near the base of the neck (C6-7). This procedure causes a short-lived shutdown of sympathetic nerve signals (up to 5-7 hours) and is commonly performed in Canada for certain pain and medical conditions. SGB is an interventional procedure that temporarily blocks sympathetic signaling to the arms, neck and head with long-established therapeutic benefits for sympathetically maintained pain and other medical conditions. In the past decade, SGB was found to provide a rapid and sustained reduction of PTSD symptoms in numerous case reports and series. Further, two randomized controlled trials of SGB in PTSD have been conducted. The first study in active and retired military personnel with combat and non-combat PTSD did not differentiate the effect of SGB from sham control one week or one month post-injection , although these results were inconclusive due to methodological limitations. The second study in active-duty military personnel established substantial efficacy of SGB that was administered twice in a 2-week interval when assessed at eight weeks after the first injection . Notably, most of the studies above were conducted in predominantly male active-duty military samples and none specifically in veterans, law enforcement officers, or first responders. Considering these results and the known safety of this procedure, SGB has been increasingly used to treat PTSD in the United States Veterans Affairs (VA) system, but has not yet been evaluated in Canada.
The mechanism of action of SGB in PTSD is not well understood. Presumably, SGB directly reduces peripheral sympathetic tone but may also project to the central nervous system to activate neuroplasticity processes. The current consensus is that SGB has a unique adjunct potential in PTSD treatment, but the parameters of its use and mechanism of action require further study. In order to enhance care and in response to requests from our patients and their clinicians, we initiated a collaboration between the OSI and TOH Pain clinics to facilitate access to SGB for our patients, particularly those who are not improving with traditional therapies because of intractable hyperarousal and anxiety. To date, 15 patients have undergone off-label SGB procedures at The Ottawa Hospital (TOH) Pain Clinic, seven for whom we have clinical data up to eight weeks post-SGB. We are still collecting follow-up data for the other eight patients, who had the procedure done more recently. Of those seven who underwent SGB procedures prior to October 2021, five were responders on the PTSD Checklist for DSM-5 (PCL-5), as evidenced by a 10-point decrease in the total score, between one week pre-SGB and eight weeks post-SGB. Mean Quick Inventory of Depressive Symptomatology (QIDS-SR) scores decreased from the severe to moderate range. Within 2 weeks of the procedure, one patient commented that he had "less anxiety, no panic attacks," and another reported, "It was like the entire planet felt less menacing and I felt calmer than I had in years." There were no serious adverse events related to the SGB procedure. In summary, current treatments for PTSD have shortcomings and less success in military veterans. One of the most significant challenges for recovery from PTSD is an overactive "fight-or-flight" state, fueled by the sympathetic nervous system. Patients struggle with near constant hyperarousal as they are in a state of physical and mental readiness to react to a threat. While this reaction is appropriate in dangerous situations, as a symptom of PTSD, it becomes excessive and uncontrollable, leading to persistent anxiety, irritability, agitation, startle, and sleep problems as well as triggering traumatic memories and standing in the way of regular life activities. Currently, even the best treatments for PTSD do not directly reduce hyperarousal or sympathetic activity, making it more difficult for patients to engage in and benefit from trauma-focused therapy or medications. Sufferers are often prompted to self-medicate with alcohol and other substances, which also negatively impact the patient's family and support network. This significant treatment gap calls for exploring novel ways to lessen the entrenched "fight or flight" state in those with PTSD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will receive a single 5 mL dose of 0.5% preservative-free bupivacaine.
Drug: 5 mL of 0.5% preservative-free bupivacaine
This arm will receive two 5 mL doses of 0.5% preservative-free bupivacaine.
Drug: 5 mL of 0.5% preservative-free bupivacaine
IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
Also known as: SteriMax Bupivicaine
Monitoring patient response and remission of PTSD symptoms
Proportion of patients showing response (at least 10-point reduction) and remission (total score \< 33) in symptoms of PTSD on PCL-5
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Monitoring patient improvement on Clinician Administered PTDS Scale for DSM-5 (CAPS-5)
Proportion of patients showing response (at least 10-points reduction) and loss of diagnosis on CAPS-5
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Monitoring patient improvement in symptom burden and functioning
Proportion of patients achieving reliable change (at least 14-point reduction) in the total score on OQ45.2 reflecting improvement in symptom burden and functioning
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Changes from baseline in hypervigilance
Measured by the Brief Hypervigilance Scale
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Changes from baseline in anxiety
Measured by the Overall Anxiety Severity Impairment Scale
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Changes from baseline in depression
Measured by the Quick Inventory of Depressive Symptomatology
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Changes from baseline in pain scale scores
Measured by the Brief Pain Inventory
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Ratings of participant satisfaction and recommendations for future use of SGB
Measured by qualitative self report scale
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Changes in participant's symptomatology and overall functioning from the perspective of the participant's family and support network
Measured by Family And Support Team-Questionnaire
Time frame: From pre-SGB to final study visit 12-weeks post procedure.
Plan to share: No
Started Mar 2024 (actual). Primary completion is estimated for Jan 2026, 22 months after the start.
Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
The Royal's Institute of Mental Health Research